Add Yahoo as a preferred source to see more of our stories on Google. In the past month, I’ve talked to four different people who have either had a sinus surgery or an actual sinus fungal ball, so ...

The FDA approval of the biologic drug Dupixent for allergic fungal rhinosinusitis may help patients living with this challenging condition and help them avoid repeat surgeries. The U.S. Food and Drug ...

The FDA approved dupilumab (Dupixent) for treating allergic fungal rhinosinusitis, a first for the condition, the agency announced on Wednesday. Approval stipulates use in individuals 6 years and ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a ...

Treatment with dupilumab led to significant reductions in sinus opacification, nasal congestion and nasal polyps in patients with allergic fungal rhinosinusitis. Dupilumab, an interleukin-4 receptor ...

Priority Review approval extends dupilumab into AFRS with prior surgery, expanding sino-nasal indications beyond CRSwNP and representing the ninth FDA-approved indication across type 2 inflammatory ...

A new research perspective was published in Oncoscience (Volume 10) on May 27, 2023, entitled, "Think outside the box – atypical infections in chronic sinusitis." Inflammations of the paranasal ...

Endoscopic sinus surgery for chronic rhinosinusitis (CRS) provides significantly better disease-specific quality of life at 6 months than long-term, low-dose treatment with the macrolide antibiotic ...

Patients receiving dupilumab showed clinical improvement in nasal congestion and smell, and were less likely to require systemic corticosteroids or additional sino-nasal surgery. The Food and Drug ...

When Jens Ponikau left Germany 10 years ago to do research in the United States on chronic sinus inflammation, he expected to stay nine months. Then a major breakthrough—uncovering the root cause of a ...